|
|
|
| Observation on the Therapeutic Effect of Budesonide Aerosol Inhalation on Bronchopulmonary Dysplasia |
| LI Jiang, CHEN Tie-qiang, WU Min, et al |
| Neonatal Department, Changsha Maternal and Healthcare Hospital, Changsha Hunan 410000 |
|
|
|
|
Abstract 【Objective】 To investigate the effect of Budesonide aerosol inhalation in the treatment of bronchopulmonary dysplasia (BPD) in premature infants. 【Methods】 The clinical data of 92 cases of BPD in our hospital were analyzed retrospectively. According to the treatment methods, they were divided into 29 cases of budesonide group, 34 cases of dexamethasone group and 29 cases of control group (without glucocorticoid).【Results】 After treatment, BPD scores of the budesonide group and the dexamethasone group were lighter than those of the control group, but there was no significant difference between the budesonide group and the dexamethasone group (P>0.05). Compared with the dexamethasone group and the budesonide group, the time of oxygen delivery and the time of noninvasive mechanical ventilation in the control group were significantly longer (P<0.05), but there was no significant difference in the time of hospitalization and oxygen therapy after discharge in the three groups (P>0.05). There was no significant difference in the incidence of sepsis, patent ductus arteriosus (HsPDA), intraventricular hemorrhage (IVH)≥grade Ⅲ, PVL, necrotizing enterocolitis (NEC), gastrointestinal hemorrhage, pulmonary hypertension (PPHN) and hyperglycemia among the three groups (P>0.05).【Conclusion】 For premature infants who need continuous oxygen use or ventilator use, early (≥ 14 days) use of budesonide atomization inhalation has therapeutic effect on their BPD, which can reduce the time of oxygen use and mechanical ventilation, avoid the use of glucocorticoids in the whole body, and no short-term adverse complications are found, but the long-term prognosis still needs further study.
|
|
Received: 20 March 2020
|
|
|
|
|
|
[1] Bassler D,Plavka R,Shinwell ES,et al.Early inhaled budesonide for the prevention of bronchopulmonary dysplasia[J].N Engl J Med,2015,373(16):1497-1506.
[2] Yeh TF, Chen CM, Wu SY, et al.Intratracheal administration of budesonide/surfactant to prevent bronchopulmonary dysplasia[J].Am J Respir Crit Care Med,2016,193(1):86-95.
[3] 邵肖梅,叶鸿瑁,丘小汕.实用新生儿学[M].北京:人民卫生出版社,2019:596-601.
[4] Doyle LW,Davis PG,Morley CJ,et al. Low-dose dexamethasone facilitates extubation among chronically ventilator-dependent infants: a multicenter, international,randomized,controlled trial[J].Pediatrics,2006,117(1):75-83.
[5] 张兰,沈暐,陈超,等.早产儿HsPDA危险因素及其并发症的临床分析 [J].中华全科医学, 2019, 17(8):1299-1301.
[6] Bassler D.Inhalation or instillation of steroids for the prevention of bronchopulmonary dysplasia[J].Neonatology,2015, 107(4): 358.
[7] Lex W Doyle.Late (> 7 Days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants [J].Cochrane Database Syst Rev,2017:10 (10), CD001145.
[8] van den Brink KI, Boorsma M, Staal-van den Brekel AJ, et al.Evidence of the in vivo esterification of budesonide in human airways [J].Br J Clin Pharmacol,2008,66(1):27-35.
[9] Brattsand R, Miller-Larsson A.The role of intracellular esterification in budesonide once-daily dosing and airway selectivity [J].Clin Ther,2003,25(Suppl C): C28-C41. |
|
|
|
2020, Vol. 37 
